EPSTEIN
page 2 / 366 . OCR, unverified
represents a significant departure from current dogma and may have broad applicability across the
neurodegenerativespectrum.
I have been a passionate and tireless advocate of Canavan Disease research, dedicating most of the
past 15 years of research to develop efficacious and beneficial therapeutic approaches for children
afflicted by Canavan Disease, which is a pediatric neurogenetic disease, aggressively progressive,
severely debilitating and uniformly fatal. This dedication has resulted in one prominent clinicalgene
therapy trial, with concurrent potential therapies involving stem cells and dietary supplementation
currently being pursued. The Cell and Gene Therapy Center (CGTC) combines clinical and basic
research. The CGTC serves as liaison to a large and growing international population of Canavan
EFTA00669798
--- PAGE 2 ---
patients. The focus of the CGTC's clinical work is to provide state-of-the-art clinical support to patients
as well as prenatal screening for rare mutations. Patients undergo neuroradiologic/neurometabolic
assessments at CHOP (PA) and recommendations for therapies are currently conducted in
collaboration with neurologists at NYU (NY).
My basic/clinical research for Canavan Disease has been funded by the NIH as well as charitable
Foundations. Jacob's Cure, NY, stands out as one of the most successful fundraiser and supporter of
my Canavan research and the sponsorship of Jacob's Cure donors and board of directors has been
well-recognized and visibly honored (http://jacobscure.org/events.php).
My current project on Alzheimer's Disease (AD) consists of a novel genetic therapeutic approach that
in our proof-of-concept studies has shown to significantly reduce p-amyloid plaques, promote neuronal
survival and rescue the cognitive phenotype of a well-characterized AD transgenic animal model,
carrying 5 familial mutations associated with human early-onset AD (5XFAD Mouse). I have submitted
four grant applications during the past 12 months on the basis of this promising preliminary data, but
the project remains currently unfunded. The filing of a PCT patent in support of this intervention
solicited some corporate interest that also is yet to be materialized.
I serve as scientific advisor in several Foundations and grant review panels and I have first hand
experience in review mechanisms that prioritize innovative ideas that, in part, have beenalready
published. Hence, revolutionary ideas proposed in grant applications are scored poorly in the absence
of published data. Therefore, at this stage of preclinical development, I am actively seeking the interest
of a creative and daring innovator such as yourself to support crucial interim funding required to
complete the preclinical proof-of-principle data required for a scholarly publication and future grant
funding.
Last but not least, I would like to highly commend you for choosing to fund compassionate
and remarkable projects such as raising awareness on HIV treatments in Africa while also promoting
charter schools in NY as well as heralding the first college run radio station in the US Virgin Islands
and continuing your amazing support of the Pets and Wings Program which is highly regarded by
many pet lovers, like myself.
As a scientific advisory board and grant review panel member I am a strong advocate against the
unjustified use of large animals in research and although I am not alone, as the NIH and FDA
members are restricting funding in support of large animals in biomedical research, I remain a minority
in my field and I plan not to cease the challenge. I am confident that you, as you evidently are a
compassionate individual and strive against global injustice, would support the same philosophy.
I hope you are interested in acquainting yourself with the promising AD research that I described
above.
I would be delighted to send you more detailed information and present the project to you and/or your
Foundation Assistants upon request.
I have enclosed my curriculum vitae.
EFTA00669799
--- PAGE 3 ---
Thank you in advance for your time and consideration.
I look forward to hearing from you.
Respectfully,
Paola Leone, Ph.D.
Associate Professor
Director of Cell and Gene Therapy Center
Department of Cell Biology
RowanSOM
Stratford, NJ 08084
Telephone:
FAX:
http://www.rowan.edu/som/cgtweb/
EFTA00669800
--- SOURCE: 0232__EFTA00669801.txt ---
METADATA_SOURCE: 0232
METADATA_FILENAME: EFTA00669801.pdf
----------------------------------------
From: Richard Kahn <
To: Jeffrey Epstein <jeevacation@gmail.com>
Subject: Fwd: English Translations of Ced Pin's Recommendations
Date: Tue, 27 Aug 2013 15:21:12 +0000
Attachments: Galerie_La_Ligne_ENG.doc; Laurent_TRUCHE_ENG.doc; LIFESTYLE_MGT_PIN.pdf
From Ron on Cedric's credentials..
Richard Kahn
HBRK Associates Inc.
575 Lexington Avenue, 4th Floor,
New York, New York 10022
tel
fax
cell
Begin forwarded message:
From: Globalestatemgt <
Date: August 27, 2013 8:01:55 AM EDT